Men Have Higher Risk of Parkinson's, And We May Finally Know Why
PTEN-induced kinase 1 (PINK1) protein is not normally a threat, and is important in regulating cellular energy use in the brain. However, the new research shows that in some Parkinson's cases, the immune system mistakes PINK1 for an enemy, attacking brain cells that express the protein.
According to the study, led by a team from the La Jolla Institute for Immunology in California, the PINK1-related damage done by the immune system's T cells is much more widespread and aggressive in the brains of men than women.
"The sex-based differences in T cell responses were very, very striking," says immunologist Alessandro Sette, from the La Jolla Institute for Immunology. "This immune response may be a component of why we see a sex difference in Parkinson's disease."
Using blood samples from Parkinson's patients, the researchers tested the response of the T cells in the blood against a variety of proteins previously linked to Parkinson's – finding that PINK1 stood out.
In the male Parkinson's patients, the research team noticed a six-fold increase in T cells targeting PINK1-tagged brain cells, compared with healthy brains. In the female Parkinson's patients, there was only a 0.7-fold increase.
Some of the same researchers had previously found something similar happening with T cells and the alpha-synuclein protein. However, these reactions weren't common to all Parkinson's brains, which prompted the hunt for more antigens – substances that trigger immune responses.
As is always the case with research of this type, once experts know more about how a disease gets started and how it progresses, that opens up new opportunities for finding ways to put a halt to the damage.
"We could potentially develop therapies to block these T cells, now that we know why the cells are targeting in the brain," says immunologist Cecilia Lindestam Arlehamn, from the La Jolla Institute for Immunology.
Further down the line, being able to spot these PINK1-sensitive T cells in blood samples could lead to Parkinson's disease being diagnosed at an earlier stage – which again helps with treatment and patient support.
While we're still waiting to discover a cure for Parkinson's disease, constant progress is being made in understanding the risk factors involved in its development, and new approaches to tackling it.
"We need to expand to perform more global analysis of the disease progression and sex differences – considering all the different antigens, disease severities, and time since disease onset," says Sette.
The research has been published in the Journal of Clinical Investigation.
An Ancient Disease Has Reappeared in The US. This Could Be Why.
Daylight Saving Disrupts Millions of Americans. There's a Better Way.
This Common Blood Pressure Drug Extends Lifespan And Slows Aging in Animals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
5 minutes ago
- The Hill
Alcohol drinking rate at record low: Gallup
Only 54 percent of American adults say they consume alcohol, according to Gallup, the lowest in the survey's 90-year history by one percentage point. The low metric was repeated across several demographic angles, including gender, race and age. Fifty-seven percent of men reported drinking alcohol, compared to 51 percent of women. White adults (56 percent) were four points more likely to drink than people of color (52 percent). Adults aged 35 and older (about 56 percent) were also more likely to drink than their younger counterparts (50 percent). Gallup's findings, however, varied widely by income level, consistent with previous years. Less than 40 percent of people with an annual household income of less than $40,000 reported drinking, compared to 53 percent just two years ago. About two-thirds of Americans making over $100,000 a year reported drinking — also a substantial dip from 79 percent just two years ago. Gallup's poll also found that a majority of Americans, 53 percent, say drinking in moderation ('one or two drinks a day') is bad for one's health. In 2018, only 28 percent of respondents made that claim. That perception is dominated by young people aged 18 to 34, 66 percent of whom thought drinking in moderation was detrimental to their health. The poll's findings come amid a growing shift in beliefs about whether moderate drinking, or even drinking altogether, has beneficial health effects. A series of new studies in recent years have pointed to increasing evidence that alcohol consumption is linked to cancer and other adverse health effects. The Gallup poll was conducted July 7–21. The sample size and margin of error were unclear.
Newsweek
6 minutes ago
- Newsweek
How Health Insurance Rates Could Rise In New York In 2026
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. New Yorkers could see their health insurance costs increase by up to 13 percent in 2026, according to a report. Why It Matters Health insurance is a major cost for millions of Americans, and increases could add strain to peoples' finances. Governor Kathy Hochul, a Democrat, warned in June that the "One Big Beautiful Bill Act," passed by the GOP-led Congress, could further contribute to increased health insurance premiums over the coming years l. What to Know A report from the Community Service Society (CSS), a New York nonprofit, found that insurance companies in New York's Affordable Care Act marketplace are requesting higher rates for 2026 that could cause New Yorkers who get their insurance through that marketplace to pay thousands of dollars more in insurance payments. Emblem Health Insurance Plan of Greater New York is asking for the smallest increase at only one percent, according to the report. That is an average of $170 more per person. But other companies are asking for larger increases, with the Independent Health Benefits Corporation asking for a 38 percent increase, or $3,440 more in premiums per person, according to the report. United Healthcare of New York is asking for a 37 percent increase—equating to a $5,226 increase in premiums. A stock photo shows a doctor speaking to a patient. A stock photo shows a doctor speaking to a patient. pcess609/iStock via Getty Images MVP Health Plan Inc. and Fidelis are both asking for an 8 percent increase, while MetroPlus Health Plan and Anthem are asking for 10 percent. Healthfirst PHSP and Capital District Physicians Health Plan are asking for 14 percent rises, and Oscar Insurance Corporation wants a 17 percent increase, according to the report. Highmark Western and Northeastern New York Inc. is asking for a 24 percent increase, and Excellus Health Plan is asking for a 25 percent increase, according to CSS. Peterson-KFF reported in July that individual market insurers across the country are requesting the largest premium increases in years, with some companies asking for more than 50 percent increases in ACA Marketplace plans. What People Are Saying CSS wrote in the report: "New York's individual market premiums might increase by up to 13 percent in 2026, forcing consumers to pay an extra $1,291 more annually. New York's twelve individual market carriers are requesting increases ranging from one percent by Emblem to a staggering 38 percent by Independent Health. These requests far surpass requests from carriers in other states." Governor Hochul wrote in June: "The GOP's Big Ugly bill would slash health care coverage for millions of New Yorkers and raise monthly costs by hundreds of dollars. If New York's Republican delegation won't stand up for their own constituents, I will. What Happens Next Whether these increase requests will be approved is yet to be seen. The price of health care remains a key issue facing the U.S.
Newsweek
36 minutes ago
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
